RU2021104237A - VISUALIZATION TOOLS FOR RADIOACTIVE LABELED EXOGENOUS AND ENDOGENOUS ALBUMIN - Google Patents

Claims (215)

1. Metal complex of Formula (I) or (II) or (III)

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ⁴⁺ or ^99m Tc ^{3 +} ; X is absent or selected from -NH- and -O-; R ¹ is absent or optionally substituted with C1-C18 alkyl, wherein up to and including six carbon atoms in the aforementioned C1-C18 alkyl are optionally independently replaced each with —OCH ₂ CH ₂ —; Y is absent or selected from -O-C(O)-, -C(O)-O-, -NH-C(O)-, -C(O)-NH-, -NH-C(O)-NH-, -O-C(O)-O-, -NH-C(O)-O- and -O-C(O)-NH-; R ² is optionally substituted with C1-C18 alkyl, with up to and including six carbon atoms in the aforementioned C1-C18 alkyl optionally independently each replaced with OCH ₂ CH ₂ -; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 2. The metal complex according to claim 1, characterized in that it has the structure of Formula (I)

Formula I or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ⁴⁺ or ^99m Tc ^{3 +} ; X is absent or selected from -NH- and -O-; R ¹ is absent or optionally substituted with C1-C18 alkyl, wherein up to and including six carbon atoms in the aforementioned C1-C18 alkyl are optionally independently replaced each with —OCH ₂ CH ₂ —; Y is absent or selected from -O-C(O)-, -C(O)-O-, -NH-C(O)-, -C(O)-NH-, -NH-C(O)-NH-, -O-C(O)-O-, -NH-C(O)-O- and -O-C(O)-NH-; R ² is optionally substituted with C1-C18 alkyl, with up to and including six carbon atoms in the aforementioned C1-C18 alkyl optionally independently each replaced with —OCH ₂ CH ₂ —; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 3. The metal complex according to claim 1, characterized in that it has the structure of Formula (II)

Formula (II), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ⁴⁺ or ^99m Tc ^{3 +} ; R ¹ is absent or optionally substituted with C1-C18 alkyl, wherein up to and including six carbon atoms in the aforementioned C1-C18 alkyl are optionally independently replaced each with —OCH ₂ CH ₂ —; Y is absent or selected from -O-C(O)-, -C(O)-O-, -NH-C(O)-, -C(O)-NH-, -NH-C(O)-NH-, -O-C(O)-O-, -NH-C(O)-O-, and -O-C(O)-NH-; R ² is optionally substituted with C1-C18 alkyl, with up to and including six carbon atoms in the aforementioned C1-C18 alkyl optionally independently each replaced with —OCH ₂ CH ₂ —; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 4. The metal complex according to claim 1, characterized in that it has the structure of Formula (III)

Formula (III), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ⁴⁺ or ^99m Tc ^{3 +} ; R ¹ is absent or optionally substituted with C1-C18 alkyl, wherein up to and including six carbon atoms in the aforementioned C1-C18 alkyl are optionally independently replaced each with —OCH ₂ CH ₂ —; Y is absent or selected from -O-C(O)-, -C(O)-O-, -NH-C(O)-, -C(O)-NH-, -NH-C(O)-NH-, -O-C(O)-O-, -NH-C(O)-O- and -O-C(O)-NH-; R ² is optionally substituted with C1-C18 alkyl, with up to and including six carbon atoms in the aforementioned C1-C18 alkyl optionally independently each replaced with —OCH ₂ CH ₂ —; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 5. The metal complex according to claim 1, characterized in that it has the structure of Formula (IV), (V) or (VI)

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} m=1 or 2; n=1-5; o=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 6. The metal complex according to claim 5, characterized in that it has the structure of Formula (IV)

Formula (IV), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} m=1 or 2; n=1-5; o=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 7. The metal complex according to claim 5, characterized in that it has the structure of Formula (V)

Formula (V), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ⁴⁺ or ^99m Tc ^{3 +} ; n=1-5; o=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 8. The metal complex according to claim 5, characterized in that it has the structure of Formula (VI):

Formula (VI), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} ; n=1-5; o=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 9. The metal complex according to claim 1, characterized in that it has the structure of Formula (VII), (VIII) or (IX)

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} ; m=1 or 2; n=1-5; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 10. The metal complex according to claim 9, characterized in that it has the structure of Formula (VII)

Formula (VII), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} ; m=1 or 2; n=1-5; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 11. The metal complex according to claim 9, characterized in that it has the structure of Formula (VIII):

Formula (VIII), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} ; n=1-5; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 12. The metal complex according to claim 9, characterized in that it has the structure of Formula (IX)

Formula (IX), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ⁴⁺ or ^99m Tc ^{3 +} ; n=1-5; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 13. The metal complex according to claim 1, characterized in that it has the structure of Formula (X), (XI) or (XII)

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ⁴⁺ or ^99m Tc ^{3 +} ; p=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 14. The metal complex according to claim 13, characterized in that it has the structure of Formula (X)

Formula (X), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} ; p=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 15. The metal complex according to claim 13, characterized in that it has the structure of Formula (XI)

Formula (XI), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} ; p=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 16. The metal complex according to claim 13, characterized in that it has the structure of Formula (XII)

Formula (XII), or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, where M is ¹¹¹ In ^{3 +} , ⁶⁷ Ga ^{3 +} , ^99m Tc ^{4 +} , or ^99m Tc ^{3 +} ; p=1-12; and TBG is a thiol-linking group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridyldithio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylenic group. 17. The metal complex according to any one of paragraphs. 1-16, its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, wherein TBG is an optionally substituted maleimide group. 18. The metal complex according to any one of claims 1 to 17, its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, characterized in that TBG is

. 19. The metal complex according to any one of paragraphs. 1-18, its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, characterized in that M is ¹¹¹ In ^{3 +} . 20. The metal complex according to claim. 1, characterized in that the specified metal complex is selected from

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof. 21. The metal complex according to claim. 1, characterized in that the specified metal complex is selected from

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof. 22. The metal complex according to claim. 1, characterized in that the specified metal complex is selected from

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof. 23. The metal complex according to claim. 1, characterized in that the specified metal complex is selected from

or its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof. 24. The metal complex according to any one of paragraphs. 1-23, characterized in that the countercation of a pharmaceutically acceptable salt is selected from: one or two Na ⁺ , K ⁺ , or NH ₄ ⁺ ; or one Ca ²⁺ or Mg ^{2 +} . 25. Pharmaceutical composition, comprising: a) metal complex according to any one of paragraphs. 1-24, its conjugate acid, or a pharmaceutically acceptable salt or hydrate thereof, and b) a pharmaceutically acceptable carrier. 26. Pharmaceutical composition according to claim 25, characterized in that the metal complex covalently binds to the thiol group of cysteine-34 of endogenous or exogenous albumin. 27. A method for diagnosing a disease in a subject, wherein said disease is selected from cancer, a viral disease, an autoimmune disease, an acute or chronic inflammatory disease, and a disease caused by bacteria, fungi, or other microorganisms, comprising administering to the aforementioned subject a diagnostically effective amount of a metal complex according to any one of pp. 1-24 or a pharmaceutical composition according to claim 25 or 26 and then subjecting said subject to imaging by SPECT (single photon emission computed tomography). 28. The method according to claim 27, characterized in that the disease is cancer. 29. A method for diagnosing cancer in a subject, comprising administering to a subject a detectable amount of a metal complex according to any one of paragraphs. 1-24 or the pharmaceutical composition of claim 25 or 26; performing imaging on said subject after administration of the metal complex or pharmaceutical composition to detect a signal from the radioactively labeled metal complex, wherein detection of the presence of said signal from a radioactive isotope in the tissue indicates that the tissue is malignant, thereby diagnosing cancer in the subject. 30. A method for diagnosing cancer in a subject, comprising administering to the subject a detectable amount of a metal complex according to any one of claims 1 to 24 or a pharmaceutical composition according to claim 25 or 26; performing visualization of the specified subject after the introduction of the metal complex or pharmaceutical composition to detect a signal from the radioactive label of the metal complex, wherein detection in the tissue of increased signal accumulation from said radioactive label compared to non-malignant tissue of the same type indicates that the tissue is malignant, thereby diagnosing cancer in the subject. 31. A method for diagnosing cancer in a subject, comprising administering to the subject a metal complex according to any one of paragraphs 1-24 or a pharmaceutical composition according to paragraphs 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; subjecting said subject to imaging after administration of the metal complex or pharmaceutical composition to detect a signal from the radioactive label of the metal complex, wherein detecting the presence of a signal from the radioactive label in the tissue indicates that the tissue is malignant, thereby diagnosing cancer in the subject. 32. A method of treating cancer in a subject, comprising introduction to the subject of the metal complex according to any one of paragraphs. 1-24 or the pharmaceutical composition of claim 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; subjecting said subject to imaging after administration of the metal complex or pharmaceutical composition to detect a signal from the radioactive label of the metal complex, wherein detecting the presence of a signal from the radioactive label in the tissue indicates that the tissue is malignant; diagnosing the subject with cancer in said tissue; and administering to the subject a therapeutically effective amount of the chemotherapeutic agent. 33. A method for diagnosing cancer in a subject that is susceptible to an albumin-binding chemotherapeutic agent, comprising introduction to the subject of the metal complex according to any one of paragraphs. 1-24 or a pharmaceutical composition according to claim 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; subjecting the subject to imaging after administration of the metal complex or pharmaceutical composition to detect a signal from the radioactive label of the metal complex, wherein detecting the presence of said signal from the radioactive label in the tissue indicates that the tissue is malignant; diagnosing the subject with cancer that is sensitive to therapy with an albumin-binding chemotherapeutic agent. 34. A method of treating a cancer subject that is susceptible to an albumin-binding chemotherapeutic agent, comprising administering to the subject a metal complex according to any one of paragraphs. 1-24 or the pharmaceutical composition of claim 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; performing imaging on the subject after the introduction of a metal complex or a pharmaceutical composition to detect a signal from the radioactive label of the metal complex, while detecting the presence of the specified signal from the radioactive label in the tissue indicates that the tissue is malignant, diagnosing the subject with cancer that is susceptible to therapy with an albumin-binding chemotherapeutic agent; and administering to the subject a therapeutically effective amount of said albumin-binding chemotherapeutic agent. 35. A method comprising introduction to the subject of the metal complex according to any one of paragraphs. 1-24 or the pharmaceutical composition of claim 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; subjecting the subject to imaging after administration of the metal complex or pharmaceutical composition to detect a signal from the radioactive label of the metal complex, wherein detecting the presence of said signal from the radioactive label in the tissue indicates that the tissue is malignant; diagnosing the subject with cancer in said tissue; and administering to the subject a therapeutically effective amount of an albumin-binding chemotherapeutic agent. 36. A method comprising introduction to the subject of the metal complex according to any one of paragraphs. 1-24 or the pharmaceutical composition of claim 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; subjecting the subject to imaging after administration of the metal complex or pharmaceutical composition to detect a signal from the radioactive label of the metal complex, wherein detecting the presence of said signal from the radioactive label in the tissue indicates that the tissue is malignant; diagnosing the subject with cancer in said tissue; classifying the subject as susceptible to an albumin-binding chemotherapeutic agent; and administering to the subject a therapeutically effective amount of said albumin-binding chemotherapeutic agent. 37. A method for assessing the sensitivity of a subject with cancer to an albumin-binding chemotherapeutic agent, comprising introduction to the subject of the metal complex according to any one of paragraphs. 1-24 or a pharmaceutical composition according to claim 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; subjecting the subject to imaging after administration of the metal complex or pharmaceutical composition to detect a signal from the radioactive label of the metal complex, wherein the presence of said signal from the radioactive label in the tissue indicates that the tissue is malignant; diagnosing the subject with cancer in said tissue; and classifying said subject as susceptible to an albumin-binding chemotherapeutic agent. 38. A method for assessing the susceptibility of a cancer in a subject to an albumin-binding chemotherapeutic agent, comprising introduction to the subject of the metal complex according to any one of paragraphs. 1-24 or a pharmaceutical composition according to claim 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in malignant tissue; subjecting the subject to imaging after administration of the metal complex or pharmaceutical composition to detect the presence of a signal from the radioactive label of the metal complex, wherein detecting the presence of said signal from the radioactive label in the tissue indicates that the tissue is malignant; diagnosing the subject with cancer in said tissue; and classifying said cancer in the subject as susceptible to an albumin-binding chemotherapeutic agent. 39. A method for evaluating the ability of an albumin-binding chemotherapeutic agent to treat cancer in a subject, comprising introduction to the subject of the metal complex according to any one of paragraphs. 1-24 or a pharmaceutical composition according to paragraphs. 25 or 26, wherein the metal complex binds to albumin to form a metal complex-albumin conjugate, and said metal complex-albumin conjugate accumulates in the malignant tissue; performing imaging on the subject after administration of a metal complex or a pharmaceutical composition to detect a signal from a radioactive label of the metal complex, while detecting the presence of said signal from a radioactive label in malignant tissue indicates that the albumin-binding chemotherapeutic agent is able to treat cancer in said subject. 40. The method according to any one of paragraphs. 27-39, characterized in that the metal complex is administered in the form of a metal complex-albumin conjugate obtained ex vivo. 41. The method of claim 40, characterized in that the metal complex-albumin conjugate is obtained by conjugating albumin with a fragment corresponding to the TBG group in the metal complex, followed by chelation with M. 42. The method of claim 40, characterized in that the metal complex-albumin conjugate is obtained by chelation with M to form a metal complex, followed by conjugation of albumin with the TBG group of said metal complex to obtain a metal complex-albumin conjugate. 43. The method according to any one of paragraphs. 27-42, characterized in that said cancer is selected from adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullar carcinoma, anal carcinoma, astrocytoma, basalioma, pancreatic cancer, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma , breast cancer, Burkitt's lymphoma, uterine body cancer, malignant tumor syndrome with no known primary site (CUP), colon cancer, small intestine cancer, ovarian cancer, endometrial carcinoma, gallbladder cancer, gallbladder carcinoma, uterine cancer, cervical cancer uterus, neck, nose and ear tumors, hematologic neoplasia, hairy cell leukemia, urethral cancer, skin cancer, gliomas, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal carcinoma, head/neck tumors, colon carcinoma, craniopharyngioma, cancer liver, leukemia, lung cancer, non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma gastric cancer, colon cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinoma, oligodendroglioma, esophageal carcinoma, osteoplastic carcinoma and osteolytic carcinoma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, penile cancer, prostate cancer, tongue cancer, ovarian carcinoma, and lymph node cancer. 44. A kit for diagnosing the susceptibility of a subject with cancer to an albumin-binding chemotherapeutic agent, where the above kit includes a metal complex according to any one of paragraphs. 1-24 or a pharmaceutical composition according to claim 25 or 26. 45. The use of the metal complex according to any one of paragraphs. 1-24 for making a medicament for diagnosing cancer in a subject. 46. The use of the metal complex according to any one of paragraphs. 1-24 for making a medicament for diagnosing cancer in a subject that is sensitive to an albumin-binding chemotherapeutic agent. 47. The use of the metal complex according to any one of paragraphs. 1-24 for making a medicament for assessing a subject's susceptibility to an albumin-binding chemotherapeutic agent. 48. The use of a metal complex according to any one of paragraphs. 1-24 for the manufacture of a medicament for assessing the susceptibility of a cancer in a subject to an albumin-binding chemotherapeutic agent. 49. Application according to any one of paragraphs. 45-48, characterized in that said cancer is selected from adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullar carcinoma, anal carcinoma, astrocytoma, basalioma, pancreatic cancer, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinomas, breast cancer, Burkitt's lymphoma, endometrial cancer, cancer syndrome without a known primary site (CUP), colon cancer, small intestine cancer, ovarian cancer, endometrial carcinoma, gallbladder cancer, gallbladder carcinomas, uterine cancer, cancer cervix, neck, nose and ear tumors, hematologic neoplasia, hairy cell leukemia, urethral cancer, skin cancer, gliomas, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal carcinoma, head/neck tumors, colon carcinomas, craniopharyngioma, liver cancer, leukemia, lung cancer, non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's mfoma, gastric cancer, colon cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinoma, oligodendroglioma, esophageal carcinoma, osteoplastic carcinoma and osteolytic carcinoma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, penile cancer, prostate cancer, tongue cancer, ovarian carcinoma, and lymph node cancer. 50. The metal complex according to any one of paragraphs. 1-24 for use in diagnosing cancer in a subject. 51. The metal complex according to any one of paragraphs. 1-24 for use in diagnosing cancer in a subject that is susceptible to an albumin-binding chemotherapeutic agent. 52. The metal complex according to any one of paragraphs. 1-24 for use in assessing the susceptibility of a cancer in a subject to an albumin-binding chemotherapeutic agent. 53. The metal complex according to any one of paragraphs. 1-24 for use in assessing the susceptibility of a cancer in a subject to an albumin-binding chemotherapeutic agent. 54. The metal complex according to any one of paragraphs. 1-24 for use in evaluating the ability of an albumin-binding chemotherapeutic agent to treat cancer in a subject.